Treating people with IBS: a randomised double-blind placebo controlled trial of IntestAidIB in people with Irritable Bowel Syndrome (IBS)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN67764449

Enrollment

Registered

2005-12-15

Start date

2004-10-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome (IBS) Digestive System Irritable bowel syndrome (IBS)

Interventions

Treatment by nucleotide supplements for 8 weeks and placebo for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants should be aged 18?65, should have been diagnosed as having IBS by a qualified medical practitioner, and should have diarrhoea as a main symptom.

Exclusion criteria

Exclusion criteria: Any other co-existing illnesses, and non-confirmation of the diagnosis by GP.

Design outcomes

Primary

Measure	Time frame
Improvement in daily ratings of seven symptoms of IBS (self report) above placebo level.	—

Secondary

Measure	Time frame
Improvement in anxiety and depression ratings (self report) following experimental condition.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026